ArticleBMC pediatrics2026
Clinical and virological impacts of human parvovirus B19 epidemics on fulminant myocarditis in childhood.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOutbreaks of pediatric myocarditis and increased activity of human parvovirus B19 (B19V) have been reported worldwide following the coronavirus disease 2019 (COVID-19) pandemic. However, the direct association between prevalent erythema infectiosum and fulminant myocarditis (FM) remains elusive because of the lack of surveillance data. This study aimed to evaluate the incidence of pediatric FM during the prolonged period and to characterize B19V genotypes and clinical outcomes of the positive cases for improved disease control.
methodsPediatric patients with FM retrospectively underwent clinical and comprehensive virological analyses at one of the largest tertiary centers in Japan from 2009 to 2024, encompassing three epidemic periods of erythema infectiosum. The incidence of FM with and without B19V infection was analyzed using a Poisson regression model. Clinical and laboratory findings were compared between B19V-positive and B19V-negative patients. Genotypic variations of the isolated B19V strains were also examined.
resultsTwenty-one (median age: 5 years, range: 1 month–14 years) of 33 patients underwent viral study. Eight (38%) patients were positive for B19V DNA (1.15–6.11 log10 copies/ml). The incidence of B19V-positive FM in the three epidemic periods was significantly greater than that in the other study periods (1.33/year vs. 0.26/year, incidence rate ratio: 5.1 [1.2–21], p = 0.03). The youngest B19V-positive patient was a 4-month-old infant with a sufficient B19V-specific IgG level at presentation. B19V-specific IgM levels were positively correlated with the viral loads under the cutoff diagnostic index for erythema infectiosum (correlation coefficient: 0.970, p = 0.0005). B19V-positive patients showed higher cardiac enzyme levels, lower ejection fractions on admission, and higher mortality rates (50% vs. 15%) than B19V-negative patients. However, no cardiac outcomes differed among survivors. All six isolated B19V strains belonged to the genotype 1, representing the background virus strains isolated from five non-myocarditis controls.
conclusionsB19V-induced FM associated with epidemic strains, causing severe myocardial destruction. Rapid circulating B19V DNA testing rather than serologic testing helps guide intensive intervention for pediatric myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.